Monoamine oxidase inhibitory properties of optical isomers and N-substituted derivatives of 4-methylthioamphetamine

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 18, Issue 4, 2003, Pages 339-347

  Hurtado Guzmán, Claudio ^a   Fierro, Angélica ^b   Iturriaga Vásquez, Patricio ^a   Sepúlveda Boza, Silvia ^b   Cassels, Bruce K ^a   Reyes Parada, Miguel ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

Author keywords

4 methylthioamphetamine; Amphetamine derivatives; Antidepressants; MAO inhibitors; Monoamine oxidase; Structure activity relationships

Indexed keywords

1 (4 METHYLTHIOPHENYL) 2 AMINOBUTANE; 1 (4 METHYLTHIOPHENYL) 2 AMINOPROPANE; 4 METHYLTHIOAMPHETAMINE DERIVATIVE; ETHANE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; N ETHYL 1 (4 METHYLTHIOPHENYL) 2 AMINOPROPANE; N METHYL 1 (4 METHYLTHIOPHENYL) 2 AMINOPROPANE; N PROPYL 1 (4 METHYLTHIOPHENYL) 2 AMINOPROPANE; N,N DIETHYL 1 (4 METHYLTHIOPHENYL) 2 AMINOPROPANE; N,N DIMETHYL 1 (4 METHYLTHIOPHENYL) 2 AMINOPROPANE; N,N DIPROPYL 1 (4 METHYLTHIOPHENYL) 2 AMINOPROPANE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN MITOCHONDRION; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; ENZYME INHIBITION; IN VITRO STUDY; ISOMERISM; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUSPENSION CELL CULTURE;

AMPHETAMINES; ANIMALS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

GYMNOMYZA SAMOENSIS;

EID: 0041695613     PISSN: 14756366     EISSN: None     Source Type: Journal    
DOI: 10.1080/1475636031000118437     Document Type: Article

References (31)

1. Murphy, D.L. (1978) Biochem. Pharmacol. 27, 1889-1893.
2. Johnston, J.P. (1968) Biochem. Pharmacol. 17, 1285-1297.
3. Bach, A.W.J., Lan, N.C., Johanson, D.L., Abell, C.W., Bembenek, M.E., Kwan, S.W., Seeburg, P.H. and Shih, J.C. (1988) Proc. Natl. Acad. Sci. USA 85, 4934-4938.
4. Youdim, M.B.H. (1983) Mod. Prob. Pharmacopsychiat. 19, 63-74.
5. Murphy, D.L., Aulakh, C.S., Garrik, N.A. and Sunderland, T. (1987) In: Meltzer, H.Y., ed, Psychopharmacology: The Third Generation of Progress (Raven Press, New York), pp 545-552.
6. Shulman, K.I. (1994) In: Kennedy, S.H., ed, Clinical Advances in Monoamine Oxidase Inhibitor Therapies (American Psychiatric Press, Washington, DC), pp 111-124.
7. Möller, H.-J., Paykel, E.S., eds. (1992) Renaissance of Monoamine Oxidase Inhibitors: the New Selective and Reversible Generation (Royal Society of Medicine, London).
8. Waldmeier, P.C., Amrein, R. and Schmid-Burgk, W. (1994) In: Kennedy, S.H., ed, Clinical Advances in Monoamine Oxidase Inhibitor Therapies (American Psychiatric Press, Washington, DC), pp 33-59.
9. Bieck, P.R. and Antonin, K-H. (1994) In: Kennedy, S.H., ed, Clinical Advances in Monoamine Oxidase Inhibitor Therapies (American Psychiatric Press, Washington, DC), pp 83-110.
10. Mantle, T.J., Tipton, K.F. and Garrett, N.J. (1976) Biochem. Pharmacol. 25, 2073-2077.
11. Florvall, L., Ask, A-L., Ögren, S-O. and Ross, S.B. (1978) J. Med. Chem. 21, 56-63.
12. Fuller, R.W. and Hemrick-Luecke, S.K. (1982) Res. Commun. Substance Abuse 3, 159-164.
13. Green, A.L. and El Hait, M.A.S. (1980) J. Pharm. Pharmacol. 32, 262-266.
14. Scorza, M.C., Carrau, C., Silveira, R., Zapata-Torres, G., Cassels, B.K. and Reyes-Parada, M. (1997) Biochem. Pharmacol. 54, 1361-1369.
15. Huang, X., Marona-Lewicka, D. and Nichols, D.E. (1992) Eur. J. Pharmacol. 229, 31-38.
16. Scorza, M.C., Silveira, R., Nichols, D. and Reyes-Parada, M. (1999) Neuropharmacol. 38, 1055-1061.
17. Elliott, S.P. (2000) J. Anal. Toxicol. 24, 85-89.
18. Elliott, S.P. (2001) Ann. Clin. Biochem. 38, 339-347.
19. Winstock, A.R., Wolf, K. and Ramsey, J. (2002) Drug Alcohol Depend. 67, 111-115.
20. Dale, J.A. and Mosher, H.S. (1973) J. Am. Chem. Soc. 92, 512-519.
21. Reyes-Parada, M., Scorza, M.C., Silveira, R., Dajas, F., Costa, G., Tipton, K.F. and Cassels, B.K. (1994) Biochem. Pharmacol. 47, 1365-1371.
22. Holland, G.F., Buck, C.J. and Weissman, A. (1963) J. Med. Chem. 6, 519-524.
23. Murphy, J.E.J., Flynn, J.J., Cannon, D.M., Guiry, P.J., McCormack, P., Baird, A.W., McBean, G.J. and Keenan, A.J. (2002) Eur. J. Pharmacol. 444, 61-67.
24. Dukat, M., Young, R. and Glennon, R.A. (2002) Pharmacol. Biochem. Behav. 72, 299-305.
25. Florvall, L., Ask, A-L., Ross, S.B., Ögren, S-O. and Holm, A-Ch. (1983) Acta. Pharm. Suec. 20, 255-270.
26. Robinson, J.B. (1985) Biochem. Pharmacol. 34, 4105-4108.
27. Aliste, M.P. and Cassels, B.K. (2001) J. Chem. Soc., Perkin Trans. 2, 906-915.
28. Ask, A-L., Fagervall, I., Florvall, L., Ross, S.B. and Ytterborn, S. (1985) Br. J. Pharmacol. 85, 683-690.
29. Fowler, C.J. and Oreland, L. (1981) J. Pharm. Pharmacol. 33, 403-406.
30. Leonardi, E.T.K. and Azmitia, E.C. (1994) Neuropsychopharmacol. 10, 231-237.
31. Nichols, D.E. (1994) In: Cho, A.K. and Segal, D.S., eds, Amphetamine and Its Analogs. Psychopharmacology Toxicology and Abuse (Academic Press, San Diego, California), pp 3-41.